What is Regeneron's REGN-COV2? The experimental Covid drug given to Trump

President Trump was given an artificial antibody treatment REGN-COV2. Credit: AP/Press Association Images

The experimental coronavirus drug given to Donald Trump is "very promising" and "very potent", a UK doctor involved in a trial of the drug has said.

President Trump was given an artificial antibody treatment REGN-COV2, developed by Regeneron Pharmaceuticals, at the White House on Friday after he was diagnosed with Covid-19.

Mr Trump has been given the drug alongside Remdesivir, an antiviral treatment which has been shown to help some coronavirus patients recover faster, as well as zinc, vitamin D, an antacid called famotidine, melatonin and aspirin.

What is REGN-COV2 and how does it work?

REGN-COV2 is made up of two monoclonal antibodies (REGN10933 and REGN10987), which are man-made to act like human antibodies in the immune system.

It was first tested on mice which were genetically modified to have a human immune system, before being tested on 275 people, of whom 40% were classed as obese.

The antibody cocktail works by binding to a protein on the surface of the virus, stopping it from attaching to cells and replicating, while allowing the immune system to attack the virus.

Regeneron has linked up with the pharmaceutical giant Roche to increase the global supply of REGN-COV2 if it proves effective.

Regeneron CEO Dr. Leonard Schleifer attends a meeting with President Donald Trump in the Cabinet Room of the White House in March. Credit: AP

What do the experts say?

Professor Peter Horby said UK patients began receiving REGN-COV2, made by Regeneron Pharmaceuticals, last weekend as part of Oxford University’s national Recovery trial.

Prof Hornby, who specialises in emerging medicines for infectious disease, said "about three hospitals in the north" were using the drug and it could be rolled out to more than 40 others.

Details of the UK trial were announced on September 14, when Prof Horby said he expected it would also be tested on “at least 2,000” randomly allocated patients in 174 hospitals.

He said: “The class of drugs, these artificial antibodies, have been around for quite a while now, and they’ve been extensively used in inflammatory conditions and cancers, and they’re pretty safe and well understood, and so the technology is something that I think we have confidence in.

“This particular drug has probably been given to, I would think now, four or five hundred patients, mild or severe patients in different trials, and so far there’s been no worrying safety signals.

“In the laboratory, in cell cultures, it has a very strong effect against the virus, and there have been studies in artificial animals where it also shows benefits.

“So probably of the drugs that are available, it’s one of the most promising.”

Speaking on the BBC Radio 4’s Today programme, Prof Horby said a single dose of the treatment provides “prolonged protection” for “a month to six weeks”, making it “quite attractive for the older population”.

Professor Peter Horby has been involved in the trials of the experimental new drug. Credit: Pippa Fowles/10 Downing Street/Crown Copyright/PA

Nick Cammack, who is leading Covid-19 therapeutics work for Wellcome, described monoclonal antibodies as among “the most exciting” treatments for Covid-19 because they are specific to the disease, but also “traditionally the most expensive”.

He said: “Large-scale randomised controlled studies like Recovery give us the best understanding of whether drugs like REGN-COV2 are safe and effective against Covid-19, but we must ensure that any successful treatment is available to everyone who needs it globally.”